I had to revisit this one.
Here's the official title:
A Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy
The list of indicated patient recruiting parameters includes every stage of progressive papillary and follicular DTC. The list of recruiting centers is long and geographically adept - too long to substantiate the indicated enrollment of only 25 patients. The PI and the list of supporting staff clinicians represent the foremost oncologists in thyroid cancer treatment. I'm prepared to go out on a limb here...
...and suggest that this may be our label expansion trial - easily expanded to accomodate a listing into the NCCN compendia with virtually no changes to trial infrastructure.
Good things ahead.